<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763437</url>
  </required_header>
  <id_info>
    <org_study_id>TET2013</org_study_id>
    <nct_id>NCT01763437</nct_id>
  </id_info>
  <brief_title>Intralesional Tetracycline Injection in the Treatment of Chalazia</brief_title>
  <acronym>TET</acronym>
  <official_title>Intralesional Tetracycline Injection in the Treatment of Chalazia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a study to investigate the role of tetracycline injection into&#xD;
      chalazia versus observation alone. The investigators hypothesize tetracycline injection will&#xD;
      result in a significant decrease in lesion size when compared to observation alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intralesional Tetracycline Injection in the Treatment of Chalazia&#xD;
&#xD;
      Authors: Bryan R. Costin, M.D. and Julian D. Perry, M.D.&#xD;
&#xD;
      Purpose: To investigate the therapeutic role of intralesional tetracycline injection when&#xD;
      compared to observation alone in the treatment of chalazia.&#xD;
&#xD;
      Introduction:&#xD;
&#xD;
      The tetracycline family includes tetracycline, doxycycline, and minocycline and this group of&#xD;
      compounds has a surprising number of properties including but not limited to antibiotic,&#xD;
      anti-malarial, anti-inflammatory, and antioxidant. Recent applications include uses both in&#xD;
      sclerotherapy in a wide variety of conditions from ganglions cysts to lymphangiomas to&#xD;
      ovarian cysts as well as in the reduction of hypertrophic scarring in rabbit models.1,2,3,4&#xD;
      In 2009, there were approximately 130 ongoing clinical trials studying this class of drugs in&#xD;
      an astounding variety of conditions from gingivitis to Alzheimer disease to brain cancer.5&#xD;
&#xD;
      Chalazia are lipogranulomatous inflammatory lesions of the eyelid and are one of the most&#xD;
      common eyelid lesions and an extremely frequent presenting complaint to the ophthalmologist.&#xD;
      Chalazia often represent significant morbidity for the patients suffering from these lesions&#xD;
      because they are often recurrent, can be refractory to treatment, and are disfiguring.&#xD;
      Consequently, chalazia can also be a challenge to the ophthalmologist. Oral tetracyclines&#xD;
      have been shown to be effective in the treatment of ocular rosacea and meibomian gland&#xD;
      dysfunction (MGD), which are conditions commonly seen in association with chalazia. The&#xD;
      anti-inflammatory effect of the tetracyclines is thought to be beneficial in rosacea and&#xD;
      these drugs have been shown to alter the fatty acid composition of the lipid layer of the&#xD;
      tear film perhaps explaining their efficacy in MGD.6&#xD;
&#xD;
      Chalazia eventually resolve without intervention, but the process can take many months and&#xD;
      patients are frequently dissatisfied with observation as a treatment modality. Often patients&#xD;
      choose incision and drainage (I&amp;D) of the lesion and this method is often successful. Another&#xD;
      treatment shown to be effective in chalazion treatment is the injection of corticosteroid&#xD;
      directly into the lesion, hence providing a depot anti-inflammatory effect.7 However, unlike&#xD;
      corticosteroids, the tetracyclines would offer antibiotic, sclerosant, and lipid tear film&#xD;
      augmentation, in addition to their anti-inflammatory effect. Further, tetracyclines are FDA&#xD;
      approved for the treatment of acne8, which is defined as inflammation of pilosebaceous&#xD;
      units9, and chalazia are defined as inflammation of sebaceous glands10. With these multiple&#xD;
      roles in mind, we propose injection of tetracycline into chalazia to investigate its use as a&#xD;
      multipurpose depot.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      After IRB approval, chalazia patients who wish to participate will be enrolled after the&#xD;
      risks, benefits, alternatives, and personnel have been explained to them and informed consent&#xD;
      has been obtained. A total of 80 subjects will be randomized to one of two groups: 40&#xD;
      subjects to observation alone and 40 subjects to treatment with an intralesional injection of&#xD;
      0.05 mL 2% tetracycline solution. Subjects will be excluded from the study if they are less&#xD;
      than 18 years of age, are pregnant, have chalazia of less than 1 week duration, have known&#xD;
      allergies to tetracycline or its derivatives, or are currently taking oral tetracyclines or&#xD;
      have taken them in the past 3 months. Men, post-menopausal women, and women who have&#xD;
      undergone hysterectomy, bilateral oophorectomy, or bilateral salpingectomy will not be tested&#xD;
      for pregnancy. Pregnancy testing (urine or serum) will be performed on women of childbearing&#xD;
      age before enrollment and the results checked prior to the administration of treatment.&#xD;
&#xD;
      For patients with multiple lesions, either on the same or opposite eyelids, only the most&#xD;
      symptomatic lesion will be enrolled in the study. Eyelid margin disease and ocular rosacea&#xD;
      will be documented at the time of enrollment. Subjects will then be examined at 4 weeks (+/-&#xD;
      2 weeks) post-procedure follow-up visits where data regarding lesion size, including color&#xD;
      photography, lesion regression or recurrence, and a complete ophthalmic examination will be&#xD;
      recorded. If subjects fail to follow up at any of these visits, telephone interviews will be&#xD;
      conducted.&#xD;
&#xD;
      At the time of enrollment, the subject's date of birth, sex, race/ethnicity, and last&#xD;
      menstrual period will be determined as well as a gynecological history to determine need for&#xD;
      pregnancy testing. Data collection sheets will be used to record information. Also, previous&#xD;
      therapies including topical medications and previous surgeries will be reviewed. A millimeter&#xD;
      ruler will be used at the time of enrollment to determine the size of the lesion. Lesion&#xD;
      photographs will also be taken so that the independent chalazion photograph reviewer will be&#xD;
      able to grade degrees of improvement after treatment in a masked fashion.&#xD;
&#xD;
      When the procedure is performed, a variable pain scale will be used by the patient to&#xD;
      document their level of discomfort during the injection. At the return post procedure visit,&#xD;
      the lesion will be re-measured, the patient will be asked to grade the level of improvement&#xD;
      and a follow up photograph will be taken for use by the masked grader. All data collection&#xD;
      sheets and consents will be stored at the Cleveland Clinic in a secure location. All other&#xD;
      study data will be electronic and stored only on the secure Cleveland Clinic server or&#xD;
      Cleveland Clinic issued encrypted devices such as thumb drives and laptops. The occurrence of&#xD;
      any minor adverse or unexpected events will be reported to the principal investigator. Any&#xD;
      sentinel events will be reported to the IRB immediately.&#xD;
&#xD;
      A decrease in lesion size by two-thirds of greater as determined by either the clinician or&#xD;
      the masked photograph reviewer in either group will be considered improvement and if seen in&#xD;
      lesions injected with tetracycline it will constitute treatment success.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator left the institution&#xD;
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion size</measure>
    <time_frame>4 weeks</time_frame>
    <description>The size of the lesion will be measured as well as photographed. Photographs will be reviewed by a masked chalazion photograph reviewer.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chalazia</condition>
  <condition>Chalazion</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetracycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline</intervention_name>
    <description>Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.</description>
    <arm_group_label>Tetracycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age older than 18 years&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Chalazia of greater than 1 week duration&#xD;
&#xD;
          -  Not allergic to tetracycline or its derivatives&#xD;
&#xD;
          -  Not currently taking tetracycline or not taking them in the past 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years old&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Chalazia of less than 1 week duration&#xD;
&#xD;
          -  Allergies to tetracycline or its derivatives&#xD;
&#xD;
          -  Currently taking tetracyclines or have taken them in the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian D Perry, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Cole Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ashindoitiang JA. Preliminary report of the effectiveness of tetracycline sclerotherapy in treatment of ganglion. Plast Surg Int. 2012;2012:624209. doi: 10.1155/2012/624209. Epub 2012 Mar 26.</citation>
    <PMID>22570781</PMID>
  </reference>
  <reference>
    <citation>Chaudry G, Burrows PE, Padua HM, Dillon BJ, Fishman SJ, Alomari AI. Sclerotherapy of abdominal lymphatic malformations with doxycycline. J Vasc Interv Radiol. 2011 Oct;22(10):1431-5. doi: 10.1016/j.jvir.2011.06.021. Epub 2011 Aug 6.</citation>
    <PMID>21821431</PMID>
  </reference>
  <reference>
    <citation>Kars B, Buyukbayrak EE, Karsidag AY, Pirimoglu M, Unal O, Turan C. Comparison of success rates of 'transvaginal aspiration and tetracycline sclerotherapy' versus 'only aspiration' in the management of non-neoplastic ovarian cysts. J Obstet Gynaecol Res. 2012 Jan;38(1):65-9. doi: 10.1111/j.1447-0756.2011.01627.x. Epub 2011 Aug 10.</citation>
    <PMID>21827579</PMID>
  </reference>
  <reference>
    <citation>Henry SL, Concannon MJ, Kaplan PA, Diaz-Arias AA. The inhibitory effect of minocycline on hypertrophic scarring. Plast Reconstr Surg. 2007 Jul;120(1):80-88. doi: 10.1097/01.prs.0000263325.73400.f8.</citation>
    <PMID>17572548</PMID>
  </reference>
  <reference>
    <citation>Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. doi: 10.1152/ajpcell.00047.2010. Epub 2010 Jun 30. Review.</citation>
    <PMID>20592239</PMID>
  </reference>
  <reference>
    <citation>Souchier M, Joffre C, Gr√©goire S, Bretillon L, Muselier A, Acar N, Beynat J, Bron A, D'Athis P, Creuzot-Garcher C. Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment. Br J Ophthalmol. 2008 Jun;92(6):819-22. doi: 10.1136/bjo.2007.133900. Epub 2008 May 29.</citation>
    <PMID>18511542</PMID>
  </reference>
  <reference>
    <citation>Ben Simon GJ, Huang L, Nakra T, Schwarcz RM, McCann JD, Goldberg RA. Intralesional triamcinolone acetonide injection for primary and recurrent chalazia: is it really effective? Ophthalmology. 2005 May;112(5):913-7.</citation>
    <PMID>15878075</PMID>
  </reference>
  <results_reference>
    <citation>Lacy CF, Armstrong LL, Goldman, MP, Lance LL. Lexi-Comp's Drug Information Handbook. 13th ed. 2005. 1447.</citation>
  </results_reference>
  <results_reference>
    <citation>Wolff K, Johnson RA, et al. Fitzpatrick's Color Atlas &amp; Synopsis of Clinical Dermatology. 5th ed. McGraw-Hill. 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Macquire JI, Murchinson AP, et al. Wills Eye Institute 5-minute Ophthalmology Consult. Lippencott Williams &amp; Wilkins.</citation>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 5, 2013</study_first_submitted>
  <study_first_submitted_qc>January 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chalazia</keyword>
  <keyword>Chalazion</keyword>
  <keyword>Meibomian gland dysfunction</keyword>
  <keyword>Rosacea</keyword>
  <keyword>Ocular rosacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chalazion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

